Saturday, September 6, 2014

From the American Council on Science and Health

Me: RelaxingAbsolutely no link between bras and breast cancer.  The idea that bras somehow cause breast cancer has been circulating for years, yet it had no scientific evidence to either support or oppose it. However, the myth is finally disproved in the first study to address this issue. Read more.


Bilateral mastectomy not associated with lower mortality in breast cancer patients.  The use of bilateral mastectomy is becoming increasingly common. However, a new study finds that this most aggressive surgical strategy is not necessarily associated with lower mortality rates compared to other options. Read more.

Obesity rates steady in 44 states, but concerns still remain. New report indicates some good news on the obesity front. But this report is no reason to relax our efforts to combat this problem, as rates of obesity remain high, and two states have actually surpassed the 35% mark for the first time. Read more.

And the best diet is...all of them!  Where weight loss is concerned, it's the calories that count - not where they come from. Low-carb or low-fat diets - both can work as long as people stick to them. Perhaps we can stop arguing about which diet is best now. Read more.

Fish is more than a brain food. Your mother may have told you to each fish to 'get smart,' because it's been touted as good for the brain. Now, a new meta-analysis confirms that fish consumption confers heart benefits, and suggests why food is better than supplements. Read more.

Prostate cancer screening with PSA testing does more harm than good.  PSA screening continues at an excessive rate, likely due to patients - and, sadly, some doctors - thinking there is no downside to prostate cancer screening. A new study reminds us that the harmful effects outweigh the benefits. Read more.

Red pill plus blue pill = the end of hepatitis C? The 20-plus year race to develop effective drugs for hep C is paying off. Combination therapies are 100% effective in certain patient populations and nearly that in others. Multiple companies have drugs that are either approved or close to approval. Read more.

 

 

 

 

No comments: